(300 WORDS MAX.) The current pipeline of potential drugs for the treatment of Alzheimer Disease (AD) in clinical development trials is heavily focused on targeting the removal of amyloid plaques or decrease production of amyloid beta. Since cognitively normal individuals can live for years with amyloid plaques in their brains, evidence suggests that amyloid deposition may not be the sole cause of the cognitive decline associated with AD. Tiaki Therapeutics focuses on the hypothesis that neuroinflammation, due to microglial dysfunction, triggers the onset of clinical signs of AD. Tiaki will develop therapeutics that restore normal microglia functions, such as supporting synaptic plasticity and neuronal health, resulting in improved cognitive function in AD patients, as well as patients with other dementias.